Skip to main content

Multiple sclerosis

09-08-2018 | Multiple sclerosis | News | Article

Lower risk of disability progression in primary progressive versus progressive-relapsing MS

Superimposed relapses are associated with a lower risk of confirmed disability progression among individuals with progressive-onset multiple sclerosis, suggest the results of an observational cohort study published in JAMA Neurology.


JAMA Neurol 2018; doi:10.1001/jamaneurol.2018.210

14-02-2017 | Multiple sclerosis | News | Article

Alemtuzumab compares favorably with other potent immunotherapies for MS

Researchers suggest that alemtuzumab is comparable to natalizumab for controlling multiple sclerosis activity and superior to fingolimod and interferon beta.


Lancet Neurol 2017; Advance online publication

07-02-2017 | Multiple sclerosis | News | Article

Immunosuppression and stem cell transplants achieve sustained MS remission

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation can induce long-term remission for patients with relapsing–remitting multiple sclerosis, show findings from the HALT-MS trial.


Neurology 2017; Advance online publication

26-01-2017 | Multiple sclerosis | News | Article

News in brief

Serious adverse effect with alemtuzumab reported

Researchers have highlighted the occurrence of severely exacerbated central nervous system inflammation in two patients taking alemtuzumab for multiple sclerosis.

04-01-2017 | Multiple sclerosis | News | Article

Editor's pick

Ocrelizumab shows promise in primary progressive and relapsing–remitting MS

Phase 3 trial results have shown the benefits of ocrelizumab for reducing disability progression in patients with primary progressive multiple sclerosis and disease activity in patients with the relapsing–remitting disease subtype.


N Engl J Med 2016; Advance online publication

08-12-2016 | Multiple sclerosis | News | Article

Newborn vitamin D status linked to future MS risk

Babies born with low levels of vitamin D may be at increased risk for multiple sclerosis in later life, suggests research.


Neurology 2016; Advance online publication

image credits